177759-46-5 Usage
Description
[2-(Benzyloxy)-5-Bromophenyl]methanol, also known as a phenylmethanol derivative, is an organic compound that features a benzyl ether and a brominated aromatic structure. This white solid has a molecular formula of C14H13BrO2 and a molecular weight of 287.16 g/mol. It is characterized by its potential applications in the pharmaceutical and biochemical industries, as well as its possible biological activities and contributions to drug discovery and development.
Uses
Used in Pharmaceutical and Biochemical Industry:
[2-(Benzyloxy)-5-Bromophenyl]methanol is used as a reagent and intermediate in the pharmaceutical and biochemical industry for [application reason] its unique structural properties that allow for further chemical modifications and synthesis of various compounds.
Used in Drug Discovery and Development:
In the field of drug discovery and development, [2-(Benzyloxy)-5-Bromophenyl]methanol is used as a chemical probe for [application reason] its potential biological activities and ability to interact with specific biological targets, which may lead to the development of new therapeutic agents.
Used in Research and Development:
[2-(Benzyloxy)-5-Bromophenyl]methanol is also utilized in research and development as a compound of interest for [application reason] its unique chemical structure and potential to be modified for various applications, including the creation of new drugs or the enhancement of existing ones.
Check Digit Verification of cas no
The CAS Registry Mumber 177759-46-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,7,5 and 9 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 177759-46:
(8*1)+(7*7)+(6*7)+(5*7)+(4*5)+(3*9)+(2*4)+(1*6)=195
195 % 10 = 5
So 177759-46-5 is a valid CAS Registry Number.
177759-46-5Relevant articles and documents
COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
-
, (2018/02/28)
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
Identification of novel pyrazole acid antagonists for the EP1 receptor
McKeown, Stephen C.,Hall, Adrian,Giblin, Gerard M.P.,Lorthioir, Olivier,Blunt, Richard,Lewell, Xiao Q.,Wilson, Richard J.,Brown, Susan H.,Chowdhury, Anita,Coleman, Tanya,Watson, Stephen P.,Chessell, Iain P.,Pipe, Adrian,Clayton, Nick,Goldsmith, Paul
, p. 4767 - 4771 (2007/10/03)
The discovery, synthesis and structure-activity relationship (SAR) of a novel series of EP1 receptor antagonists is described. Pyrazole acid 4, identified from a chemical array, had desirable physicochemical properties, an excellent in vitro microsomal inhibition and cytochrome P450 (CYP450) profile and good exposure levels in blood. This compound had an ED50 of 1.3 mg/kg in a rat pain model. A range of more potent analogues in the in vitro assay was identified using efficient array chemistry. These EP1 antagonists have potential as agents in the treatment of PGE2 mediated pain.
Compounds for the treatment of ischemia
-
Page 63, (2010/02/08)
A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia
